2026 -now Board Member, Audit Committee Chair and Compensation Committee Member @ First Tracks Biotherapeutics (Nasdaq: TRAXV)
2026 -now Board Member and Audit Chair @ Helix Acquisition Corp. III (Nasdaq: HLXC)
2025 -now Board Member and Audit Chair @
2020 -now Board Member, Audit Committee Chair and Compensation Committee Member @ Design Therapeutics (Nasdaq: DSGN)
2015 -now Board Member, Audit Committee Chair and Compensation Committee Member @ AnaptysBio (Nasdaq: ANAB)
1989 -now Chairman @
2024 -2025 Board Member and Audit Chair @ Helix Acquisiton Corp. II (Nasdaq: HLXB - SPAC merged with BridgeBio Oncology Th
2017 -2025 Board Member, Audit Committee Chair, and Compensation Committee Member @ Xeris Pharmaceuticals, Inc. (Nasdaq: XERS)
2018 -2025 Board Member, Audit Committee Chair, Nom and Gov Committee Member and Lead Independent Director @ Poseida Therapeutics, Inc. (Nasdaq: PSTX - Acquired by Roche)
2017 -2024 Board Member @ Blacksmith Medicines (formerly Forge Therapeutics)
2020 -2022 Board Member and Audit Chair @ Helix Acquisition Corp. (Nasdaq: HLXA - SPAC merged with Moonlake Therapeutics)
2015 -2021 Board Member, Audit Committee Chair, and Nominating and Governance Committee Member @ Neos Therapeutics (Nasdaq: NEOS - Merged with Aytu)
2016 -2018 Board Member and Audit Committee Chair @ Patara Pharma, LLC (Acquired by Roivant)
2004 -2013 Chief Financial Officer @ Trius Therapeutics, Inc. (Nasdaq: TSRX - Acquired by Cubist)
1998 -2003 Chief Financial Officer @ GeneFormatics, Inc. (Merged with Structure Function Genomics)
1995 -1998 Chief Financial Officer @ Endonetics (Acquired by Medtronics)
1992 -1995 Associate @ Idanta Partners
1987 -1992 Vice President @ HomeFederal Bank
John Schmid Education
University of San Diego
MBA
1990-1992
Wesleyan University
Bachelors
1981-1985
Orono High School 1977-1981
John Schmid Skills
Biotechnology
Life Sciences
Start-ups
Financial Modeling
Investor Relations
Venture Capital
Financial Analysis
Lifesciences
Mergers
IPO
Corporate Development
Acquisition Integration
Valuation
Private Placements
Investments
Finance
Entrepreneurship
SEC filings
Executive Management
Venture Financing
Private Equity
Investment Banking
Corporate Finance
Due Diligence
Restructuring
M&A experience
Strategy
Mergers & Acquisitions
Budgets
Strategic Partnerships
Business Planning
Accounting
Angel Investing
Strategic Planning
Pharmaceutical Industry
Forecasting
Management
Commercialization
Financial Structuring
Biopharmaceuticals
Public Companies
Corporate Governance
Sarbanes-Oxley Act
Acquisitions
Business Valuation
Financial Reporting
Divestitures
Clinical Development
Drug Discovery
Mergers and Acquisitions
Sarbanes Oxley Act
Start Ups
Project Management
Business Strategy
John Schmid Summary
John Schmid, based in Rancho Santa Fe, CA, US, is currently a Board Member and Audit Chair at BlossomHill Therapeutics, Inc.. John Schmid brings experience from previous roles at First Tracks Biotherapeutics (Nasdaq: TRAXV), Helix Acquisition Corp. III (Nasdaq: HLXC), Bright Peak Therapeutics and Design Therapeutics (Nasdaq: DSGN). John Schmid holds a 1990 - 1992 MBA @ University of San Diego. With a robust skill set that includes Biotechnology, Life Sciences, Start-ups, Financial Modeling, Investor Relations and more. John Schmid has 1 emails and 1 mobile phone numbers on RocketReach.
Get contact details of over 700M profiles across 60M companies - all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.